A Study to Evaluate the Safety, Tolerability, and Blood Levels of PF-03654746 in Subjects With Mild to Moderate Alzheimer's Disease

Pfizer logo

Pfizer

Status and phase

Terminated
Phase 1

Conditions

Alzheimer's Disease

Treatments

Drug: PF-03654746
Drug: Placebo

Study type

Interventional

Funder types

Industry

Identifiers

NCT01028911
A8801016

Details and patient eligibility

About

This is a study to evaluate the safety, tolerability and blood levels of PF-03654746 in subjects will mild to moderate Alzheimer's disease.

Enrollment

9 patients

Sex

All

Ages

55 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

* Probable Alzheimer's disease * Mini Mental State Examination score 18-26 inclusive * Aged 55-85

Exclusion criteria

* Dementia other than Alzheimer's disease * Clinically significant cardiovascular disease in the past 6 months prior to screening * Creatinine clearance \<30 mL/min

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Quadruple Blind

9 participants in 2 patient groups, including a placebo group

PF-03654746
Experimental group
Treatment:
Drug: PF-03654746
Placebo
Placebo Comparator group
Treatment:
Drug: Placebo

Trial contacts and locations

2

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems